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ABSTRACT  
Purpose: The aim of our study was to evaluate in our experience the effectiveness of 
the Radiofrequency Ablation (RFA) in the treatment of benign thyroid nodules and 
locally recurrent thyroid malignancies.  
Materials and methods: The study includes 23 patients, 15 with nodular goiter (NG) 
with contraindication or refusing surgery and 8 with inoperable recurrent well-
differentiated thyroid cancer (RTC). RFA was performed in a single session under 
ultrasound guidance, under local anesthesia and mild sedation using 18- or 19-gauge 
internally cooled, single tipped electrode with 7- and 10-mm active tips. The pre- and 
post-treatment evaluations included: contrast-enhanced ultrasound (CEUS) and 
unenhanced Computed Tomography (CT) study for the GNs, completed with contrast 
media in patients with RTCs. Of each lesion the initial volume (V), the vascularity 
and the proportion of the solid component were assessed; for NGs we also evaluated 
thyroid function, local symptoms (according to a score of 0-10 severity) and a 
cosmetic score defined by the radiologist according to a 1-4 scale (not palpable, 
palpable but not visible, visible only during swallowing and visible in any position). 
The follow-up in 21/23 patients ranged between 6 and 18 months; 2/8 patients with 
RTCs did not undergo 6-months follow-up, respectively for systemic progression of 
disease and onset of severe comorbidity. Volume Reduction Rate was assessed 
during the follow-up and therapeutic success was defined as a> 50% VRR. Residual 
vital tissue was also assessed by using CEUS or post-contrastographic CT 
examinations. Complications were also evaluated. 
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For NGs we also tried whether there was a correlation between VRR at 6 months 
follow-up and some parameters such as age, gender, mean energy per millilitre of 
pre-treatment nodule volume, nodule initial volume, initial nodule solidity and initial 
nodule vascularity. 
Results: Mean V of lesions before treatment was 29.5 ± 24.7 mL for NGs (range: 
5.5-90ml), and 4.7 ± 3.5 ml (range: 0.8 to 8.8 ml) for RTCs. 
The mean VRR at 6, 12 and 18 months were respectively 74.3%, 79.8% and 82.3% 
for NGs. At last follow-up, the therapeutic success rate of NGs was 100% (15/15). 
The overall recurrence rate was 0% (0/15). 
We found that volume, residual vital tissue, cosmetic score and symptom score of 
NGs were significantly lower at last follow-up than before treatment (P <0.0005 for 
all comparison). Initial nodule volume, vascularity and energy delivered per millilitre 
of pre-treatment nodule volume demonstrated to be were significantly related to 6-
months VRR (P < 0.0001 for all analysis).   
The VRR of RTCs was 68.4%, 66.4% and 64.4% during the follow-up at 6, 12 and 
18 months. At last follow-up, the therapeutic success rate for RTCs was 83% (5/6) 
with overall regrowth and/or recurrence rate of 0% (0/6). 
In no case of NG treated with RFA was observed dysphonia; 3/6 patients with 
paratracheal RCT, closely adjacent to the danger triangle of the recurrent laryngeal 
nerve, have reported dysphonia (permanent in 2 cases and transient in 1 patient). 
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Conclusions: RFA demonstrated in our experience to be an effective and safe 
interventional technique and may represent a viable alternative to surgery in selected 
patients. 
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INTRODUCTION 
Thyroid nodules are very common in clinical practice, being their prevalence largely 
dependent on screening modality. It varies from 4-7% for palpable nodules to 20-
76% for nodules detected by ultrasound (US) investigation, especially due to the wide 
use in clinical practice of high-resolution US technique [1-3], according to the 
prevalence reported at autopsy that ranges from 50 and 65%. 
The clinical significance of thyroid nodules lies in their possible association with 
thyroid disfunction and compressive symptoms, but it is primarily due to their 
malignant potential [1,4]. 
Thyroid malignancies represent only 4-6,5% of all biopsied nodules and 1% of all 
cancers [1,4]; differentiated thyroid carcinoma, including papillary and follicular 
subtypes, is the most common and constitues 90% of all thyroid malignancies.  
Serum thyrotropin (TSH) and thyroid US are pivotal in the evaluation of thyroid 
nodules, as they provide important information regarding thyroid nodule functionality 
and the presence of features suspicious for malignancy. 
Although no imaging modality may accurately predict the nature of every nodule, 
high-resolution US is the most sensitive, easily available and cost-effective diagnostic 
tool available for risk stratification for malignancy in thyroid nodules. However, fine-
needle aspiration biopsy (FNAB) currently represents the best diagnostic test to 
preoperatively assess nodules nature [1,3,5].  
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Regarding to treatment, benign asymptomatic nodules are usually managed by 
observation only and follow-up while the primary thyroid cancer is always the 
prerogative of surgery.  
If the nodule is benign but causes cosmetic problems or symptoms such as dysphagia, 
foreign body sensation and hyperthiroidism or if the lesion is a local recurrence of 
thyroid carcinoma, a treatment is required and surgery is usually a better choice to 
remove the nodule effectively. The problem is that whereas thyroid surgery is widely 
available and safe in many centres, it still carries a 2 to 10% risk of complications, it 
is costly, and it may not be appropriate for a surgical high risk individual or for 
someone refusing surgery [6]. If recurrent thyroid cancer is detected several years 
after primary surgical intervention, significant risks may be associated with 
comorbidity and with scars from previous operations; this group of patients has 
undergone total thyroidectomy, radioactive iodine ablation and many have also had 
lymph node dissections, thus cervical anatomic planes are distorted. A nonsurgical 
and minimally invasive treatment modality is needed as an alternative in these 
patients. When it refers to benign thyroid nodule but with compressive symptoms, 
surgical intervention has some disadvantages such as leaving scar tissue in the neck, 
for which the patient refuses surgery; moreover, surgery is not always feasible 
because the patient has important comorbidities or may not be intubated for the 
presence of severe tracheal compression by the goiter. Radioiodine therapy and 
suppressive therapy also presented some disadvantages. 
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Thus, a nonsurgical, minimally invasive alternative for these patients is required, 
being the US-guided ablative therapy no needing for general anesthesia, no scarring, 
requiring earlier recovery to normal lifestyle, and burdened with fewer complications.  
Ethanol Ablation (EA) [7,8] and Laser Ablation (LA) [9] have been tried previously in 
such scenarios.  
Since 1998, Radiofrequency Ablation (RFA) has also been introduced to ablate 
thyroid malignancies and benign thyroid nodules [10]. Since that time, several papers 
have been published about RFA in thyroid glands, demonstrating the efficacy and 
safety of RFA for treating benign non-functioning, autonomously functioning thyroid 
nodules [11-16] and local recurrence from well differentiated malignancies [17-20].  
The efficacy of RFA for reducing benign nodule volume and relieving nodule-related 
clinical problems has been recently confirmed by the prospective comparison study 
by Baek et al. using a control group [21] and by Lim et al. that reported a mean 
volume reduction rate of 93.4% in a four-years follow-up period [22]. 
In patients with locally recurrent thyroid cancer RFA also demonstrated to be 
effective for maintaining locoregional control of their cancer [17–20], being reported a 
mean volume reduction of 56–93% [19, 20].  
The aim of our study was to determine the efficacy of Ultrasound-guided 
Radiofrequency Ablation in our experience in the treatment of symptomatic benign 
thyroid nodules and recurrent well-differentiated thyroid cancers. 
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MATERIALS AND METHODS 
Patients 
Twenty-three nodules in 23 patients judged ineligible for surgery or refusing surgery 
were treated with single-session US-guided RFA at our Institution. Fiftheen out of 23 
lesions were benign nodules in patients (12 females, 3 males; mean ± SD age, 57,8 ± 
9,9 years; range, 39-73 years) with nodular goiter (NG) reporting cosmetic and/or 
symptomatic problems. Eight patients (2 females, 4 males; mean ± SD age, 68 ± 9,8 
years; range, 53-83 years) presented with regional recurrence from well-differentiated 
thyroid carcinoma (RTC). Citologically confirmation of benign or malignant nature, 
respectively, was obtained on two separate US-guided FNAB for each patient.  
 
Pre-ablation assessment 
All patients were evaluated by baseline and contrast-enhanced ultrasound (CEUS) 
examination (7,5 MHz, MyLab Twice, Esaote, Italy). 
Unenhanced and post-contrastographic computed tomography (CT) examination 
(Light Speed VCT, General Electric, USA) of the neck was also performed for all 
RTCs; baseline CT scan was also done for large benign nodules (> 20 mL).  
The volume of each nodule was calculated before RF ablation as V= πabc/6 (where V 
is volume, a is the largest diameter, and b and c the two other orthogonal diameters). 
Nodule vascularization was assessed before treatment by evaluating lesions contrast 
enhancement using three-point scale, with grade 1, 2 and 3 defined respectively as 
diffusely low, inhomogeneously moderate and diffusely high vascularity.  
The proportion of solid component, defined as nodular component showing contrast 
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medium uptake, was also evaluated. Fluid component of mixed type nodules was 
previously aspirated in order to obtain only predominantly solid lesions (solid 
component > 85%). Furthermore, all patients with NG were asked to rate pressure 
symptoms on a 10-cm visual analogue scale (0–10 cm), and the physician recorded a 
cosmetic grade (1, no palpable mass; 2, invisible but palpable mass; 3, mass visible 
on swallowing only; and 4, easily visible mass) [23-25]. Laboratory examinations for 
patients with NG included measurements of serum thyrotropin, total triiodothyronine 
and free thyroxine concentrations. 
 
Procedure 
A written informed consent document, explaining possible complications, was 
obtained from all patients before the procedure.  
RF ablation was performed on inpatients who had been hospitalized during the 
previous afternoon and discharged the morning after treatment. 
Platelet count and blood coagulation tests, including prothrombin time and activated 
partial thromboplastin time were required to be normal. 
Before ablation, an intravenous route was made via the antecubital vein of the arm for 
the intravenous administration of sedative drugs, being the procedure performed 
under mild sedation. The patients were treated with 2% lidocaine for local anesthesia 
at the puncture site. To prevent unnecessary scar formation, the skin was not incised. 
All RF ablations were performed by using a RF generator (VIVA RF generator, 
STARmed, Korea) and 18- or 19-gauge internally cooled, single tipped electrode 
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with 7- or 10-mm active tip. In this study we treated only one nodule per patient; if 
the patient had a multinodular goiter, we treated the nodule of most cosmetic or 
symptomatic concern. Under US guidance, we performed RF ablation of benign 
nodules using transisthmic approach and moving shot technique, as previously 
described [11,12,21,23]. Small regional recurrences of thyroid cancer were treated by 
mostly using a vertical approach being the electrode fixed during ablation. One 
puncture of the skin and thyroid capsule was made in all patients. 
During the procedure, we payed special attention to the preservation of surrounding 
important organs to prevent significant complication such as nerve injury. 
Ablation was begun with 30–35 Watt of RF power. If a transient hyperechoic zone 
did not form at the electrode tip within 5–10 s, RF power was increased in 5 W 
increments to a maximum of 45 W, depending on the size of the active tip and the 
internal characteristics of each nodule. 
CEUS examinations were performed during procedure to better assess residual 
vascularized tissue. The ablation procedure was terminated when all conceptual units 
had become unenhancing zones. Immediate complications were evaluated 
periprocedurally. 
 
Follow-up 
Patients were followed-up by US and CT examinations as in the pre-ablation 
assessment. Mean follow-up period was 10,4 months for NGs and 13 months for 
RTCs (range between 6 and 18 months). 
Thyroid nodule volume and Volume Reduction Rate (VRR), calculated as [(Initial 
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Volume - Final Volume/Initial Volume) x100] were assessed. Therapeutic success 
was defined as a >50 % VRR.  
Residual vital tissue was also assessed by using CEUS or post-contrastografic CT 
examinations. 
Cosmetic and symptom scores and thyroid function tests were evaluated during the 
follow-up period in the same manner as before ablation. 
For NGs we also tried whether there was a correlation between VRR at 6 months 
follow-up and some parameters such as age, gender, mean energy per millilitre of 
pre- treatment nodule volume, initial nodule volume, initial nodule solidity and initial 
nodule vascularity. 
Regrowth and/or recurrence were defined as increases in nodule volume >50% 
compared with previous US examination [26,27]. Complications were assessed 
according to clinical signs and symptoms. 
 
Statistical analysis 
All data were analysed using the statistical software package JMP for Windows 
(http://www.jmp.com). Continuous data are reported as mean ± SD (range). 
Wilcoxon signed rank tests were used to compare changes in nodule volume and in 
residual vital tissue before RF ablation and at each follow-up. Changes in cosmetic 
and symptom scores of NGs before treatment and at last follow-up were also 
evaluated by using Wilcoxon signed rank tests. 
Multiple linear regression analysis were utilized for NGs to determine a correlation 
between VRR at 6-months follow-up and some parameters such as age, gender, mean 
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energy per millilitre of pre- treatment nodule volume, initial nodule volume, initial 
nodule solidity and initial nodule vascularity. We did not perform statystical analysis 
for RTCs because of the limited population. 
Differences were considered statistically significant when the P value was less than 
0.05.  
 
RESULTS 
The baseline characteristics of the NGS and RTCs, and the initial cosmetic and 
symptom scores of the patients are summarised in Table 1 and Table 2, respectively. 
 
Tab.1 Baseline characteristics of benign thyroid nodules and patients’ cosmetic and symptom scores 
 
Tab.2 Baseline characteristics of local recurrences of well-differentiated thyroid carcinomas 
 
Follow-up period ranged between 6 and 18 months, with the mean ± SD follow-up 
duration after RF ablation being 10,4± 4,6 months (range, 6– 18 months) for NGs and 
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13 ± 5,4 months (range, 6– 18 months) for RTCs. 
Changes in thyroid nodule volume and residual vital tissue of NGs at each follow-up 
are shown in Fig. 1. Cosmetic and symptom scores improvement at last follow-up is 
illustrated in Fig. 2. The mean ± SD nodule volumes in NGs at 6, 12 and 18 months 
follow-up were 7,4±8,6 ml, 4,1±2,8 ml and 4,6±2,7 ml, respectively. We found that 
volume (7,2± 8,7 ml; range 0,6-37,4 ml), residual vital tissue (2,4±4,8 ml; range 0-
19,3 ml), cosmetic score (1,8±0,5) and symptom score (0,5±1,2) of NGs were 
significantly lower at last follow-up than before treatment (P<0,0001 for volume and 
residual vital tissue comparison; P=0,0001 and P=0,0002 for symptom and cosmetic 
scores comparison, respectively). 
 
 
 
 
 
 
 
 
Fig. 1 Changes of thyroid 
nodule volume and 
residual vital tissue before 
RF ablation and at each 
follow-up 
 
The mean ± SD VRRs of NGs at 6 months, 12 months and 18 months follow-up were 
74,3±9,7 % (range, 56,5–90%), 79,8± 8 % (range, 62,6–89%) and 83,0± 5,3 % 
(range, 77,1–90 %), respectively (Fig.3). 
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Fig. 2 Changes of 
symptom  and cosmetic 
scores before RF ablation 
and at last follow-up. 
 
At last follow-up, the therapeutic success rate for NGs was 100% (15/15) and the 
complete necrosis (considered as the absence of residual vital tissue) was obtained in 
5/15 patients (33.3 %). The overall recurrence rate was 0% (0/15). 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Changes of Volume 
Reduction Rate (VRR) 
before RF ablation and at 
each follow-up 
 
Mean total energy delivered per nodule in NGs was 36173,7±18087,3 J (range, 2303– 
74818 J), and mean energy delivered per millilitre of pre-treatment nodule volume 
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(E/ml) was 1615,4±725,6 J (range, 132,4–2572,9 J). 
Multiple linear regression analysis showed that initial nodule volume, vascularity and 
energy delivered per millilitre of pre-treatment nodule volume were significantly 
related to 6-months VRR (P<0,0001 for all analysis). Statistically significant 
relationship between VRR and above-mentioned factors are shown in Fig. 4-6. 
No patients experienced hypothyroidism nor hyperthyroidism after procedure. A 
patient suffering from hyperthyroidism because of a Plummer nodule returned to be 
euthyroid after one week to treatment and after the immediate withdrawal of therapy 
with methimazole. The overall complication rate in NGs was 0% (0/15). 
 
 
 
 
 
Fig. 4,5,6 Multiple linear regression analysis showed 
a statistically significant correlation between the 6-
months VRR and some parameters such as the initial 
nodule volume, the initial nodule vascularity and the 
energy delivered per millilitre of pre-treatment 
nodule.  
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Two out of 8 patients with RTCs did not perform 6-months follow-up because of 
systemic disease progression and the occurrence of severe comorbidity, respectively. 
Five out 6 patients presented with lesions in the surgical bed. Clinical findings, 
changes in nodule volume and VRR for each RTC at each follow-up are reported in 
Table 3 and 4. Changes in thyroid nodule volume for each RTC at 6-months, 12-
months and 18-months follow-up are shown in Fig. 7. The mean ± SD lesion volumes 
in RTCs at each follow-up were 1,6±1,7 ml, 2±1,8 ml and 2,4±1,8 ml, respectively. 
 
 
 
 
 
 
 
 
 
 
Fig. 7 
 
 
 
 
 
 
 
 
 
Tab. 3 
Fig. 7, Tab. 3 Characteristics and changes in nodule volume of each RTC at each follow-up  
 
 
Changes of VRRs of each RTC at 6 months, 12 months and 18 months follow-up are 
shown in Fig. 8. The mean ± SD VRRs were 68,4±13,4 % (range, 44,3–88,3 %), 
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66,4± 11,5 % (range, 46,6–75 %) and 64,4± 12,5 % (range, 46,6–73,3 %) at 6, 12 and 
18 months follow-up, respectively.  
At last follow-up, the therapeutic success rate for RTCs was 83% (5/6) and the 
complete necrosis (considered as the absence of vascularized tissue) was obtained in 
3/6 patients (50%). The overall regrowth and/or recurrence rate was 0% (0/6). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8 
 
 
 
 
 
 
 
 
 
Tab. 4 
Fig. 8, Tab. 4 Characteristics and changes in VRR of each RTC at each follow-up 
 
 
The overall complication rate in RTCs was 50% (3/6); major complications were 
observed in 3 patients who had paratracheal lesions, closely adjacent to danger 
 18 
 
triangle of recurrent laryngeal nerve (two reported permanent voice change and one 
presented transient dysphonia, both due to recurrent nerve injury). No patient 
experienced a life-threatening or delayed complication during follow-up. 
  
DISCUSSION 
Thyroid nodular disease is very common. The prevalence of thyroid nodules has been 
reported as 20-76% at ultrasound examination, according to the prevalence reported 
at autopsy that ranges from 50 and 65% [1-3,28]. 
If the nodule is malignant or benign but causes compressive symptoms, surgery is 
usually a better choice to remove the nodule effectively. If the patient has primary 
thyroid cancer, surgery is always the first choice, but if recurrent thyroid cancer is 
detected several years after primary surgical intervention, significant risks may be 
associated with comorbidity and with scars from previous operations; this group of 
patients has undergone total thyroidectomy, radioactive iodine ablation and many 
have also had lymph node dissections, thus cervical anatomic planes are distorted. A 
nonsurgical and minimally invasive treatment modality is needed as an alternative in 
these patients. When it refers to benign thyroid nodule but with compressive 
symptoms, surgical intervention has some disadvantages such as leaving scar tissue 
in the neck; moreover, in some patients with NG, surgery is not feasible because the 
patient has important comorbidities or may not be intubated for the presence of 
severe tracheal compression by the goiter. It calls for a nonsurgical, minimally 
invasive alternative for these patients, being the US-guided ablative therapy no 
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needing for general anesthesia, no scarring, requiring earlier recovery to normal 
lifestyle, and burdened with fewer complications.  
Ethanol Ablation (EA) [7,8] and laser Ablation (LA) [9] have been tried previously in 
such scenarios.  
Radiofrequency has also been introduced to ablate thyroid malignancies and benign 
thyroid nodules. In 1998, the first paper about radiofrequency ablation in thyroid 
disease was published by Solbiati et al [10]. Since that time, several papers have been 
published about radiofrequency ablation (RFA) in thyroid glands, demonstrating the 
efficacy and safety of RFA for treating benign non-functioning, autonomously 
functioning thyroid nodules [11–16] and local recurrence from well differentiated 
malignancies [17-20]. 
In our study we treated with RFA only solid or mainly solid nodules, both benign and 
malignant. The fluid component of mixed type benign nodules was previously 
aspirated in order to obtain only predominantly solid or solid lesions (solid 
component > 85%).  
As shown by many reports RFA is more effective than EA in the treatment of solid or 
mainly solid benign nodules, suggesting that solid components might be more 
resistant to ethanol diffusion and that the vascularity of solid nodules favors the 
drainage of ethanol; thus, the success of the procedure [29-34] results to be limited and 
multiple injections of a larger amount of ethanol are required to obtain a satisfactory 
degree of volume reduction. This may lead to greater patient discomfort or to adverse 
effects of the procedure. 
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Some reports [12,31] demonstrated that RF ablation may be also effective and safe in 
the treatment of benign predominantly cystic nodules being the volume reduction rate 
quite similar (93.1% in EA and 92.2% for RF ablation) at the 6-month follow-up [35]. 
Nevertheless, RFA has several disadvantages compared to EA, including its high cost 
and technical difficulty. Therefore, EA remains the first-line modality in the 
treatment of cystic or mainly cystic thyroid nodules [36-39]; according to these 
findings, we did not perform RFA for cystic or predominantly cystic benign nodules. 
Previous studies also suggested the usefulness of EA in the treatment of regional 
recurrent thyroid malignancies [40,41], but RF ablation demonstrated to be more 
effective than EA for these lesions even when it was used to treat larger lesions [18,42]. 
Compared with EA, RFA has also an advantage in number of treatment sessions. 
The reason for the better efficacy of RF ablation may be due to the solidity of 
recurrences and to the nonuniform ethanol diffusion unable to induce necrosis to the 
lesion border.  
Regarding to LA, RFA results demonstrated to be superior to that of laser ablation in 
a long-term follow-up, being the VRR 90–92% in RFA versus 48% in LA in a three-
years follow-up [22,23,43] and more recently, Lim et al. [22] also compared changes in 
volume of benign nodules treated with RFA to those of LA; they observed a gradual 
volume reduction in RFA treated nodules during follow-up, whereas nodules treated 
with LA tended to increase in volume at last follow-up [21,43-45] with the latter 
possibly due to the regrowth of undertreated peripheral portions of nodules [23,44,46]. 
RFA also seems to be safer than laser ablation [47].  
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The efficacy of RF ablation for reducing benign nodule volume and relieving nodule-
related clinical problems was recently confirmed by the prospective comparison 
study by Baek et al. and using a control group [21]. In five, representative studies, 
reduction of the nodule volume after RF ablation ranged from 33– 58% at one month 
and from 51–85% at six months postablation [12,14,21,46]. More recently, the mean 
volume reduction rate based on 111 patients with 126 benign thyroid nodules has 
been reported to be 93.4% four years following RF ablation [22].  
In patients with locally recurrent thyroid cancer RFA also demonstrated to be 
effective for maintaining locoregional control of cancer [17-20], being reported a mean 
volume reduction of 56–93% [19,20], and with 42–58% of the nodules disappearing 
completely [17,18,20].  
The results of our study correspond well to those study results. 
The present evaluation of 23 patients demonstrated that RF ablation resulted in 
significant reductions in the volumes of 15 benign thyroid nodules, as well as 
improving cosmetic and/or symptomatic problems for NGs. We found that the 
efficacy of RF ablation in the treatment of benign nodules was influenced by the 
initial volume (being the VRR higher for smaller lesions) and vascularity of the 
nodules, resulted RFA to be more effective in nodule with low grade of 
vascularization. Energy delivered per millilitre of pre-treatment nodule volume also 
demonstrated to be significantly related to 6-months VRR, suggesting an adequate 
energy supply.  
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We suggest that the efficacy of RF ablation is explained by the moving shot 
technique and straight internally cooled electrodes. For the moving shot technique, 
we divided thyroid nodules into multiple small conceptual ablation units and then 
performed ablation in the nodule in a unit-by-unit manner by moving the electrode 
[12,23,24,46]. This technique enabled more detailed ablation of each conceptual unit and 
of the periphery of the nodule showing the capacity to completely ablate the entire 
nodule unlike other stationary ablation methods such as in laser ablation. 
Theoretically, this technique will ablate nodules more completely because the tumor 
shape is usually ellipsoid rather than round [23]. 
We treated all nodules in a single-session ablation, according to several previous 
studies [11,13,48,49] reporting that single-session RF ablation was sufficient for 
treatment of thyroid nodules, reducing nodule volume and improving cosmetic 
problems and nodule-related symptoms. In our study no benign nodule presented a 
regrowth during the follow-up period.  
The advantage of straight internally cooled electrodes is easy movement [46], and the 
advantage of an internally cooling technique is preventing carbonization [50]. This 
electrode is shorter and thinner than that of a conventional electrode used in the liver, 
and was designed for easy control and minimal normal tissue injury.  
On the basis of previous studies [11,12,51] we proposed use of the transisthmic 
approach. An electrode approach is made from the medial to the lateral aspect of a 
targeted nodule, the short axis of the nodule, and RFA is performed in a transverse 
ultrasound view. This method has several advantages over the long-axis approach 
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(caudocranial or craniocaudal direction) and the vertical approach [13,31,52,53], firstly 
that the electrode passes through sufficient thyroid parenchyma to prevent a change 
in the position of the electrode tip during swallowing or talking. Another advantage is 
clear visualization of the relations of the thyroid nodule, electrode tip, and recurrent 
laryngeal nerve to one another in order to minimize the risk of injury to the recurrent 
laryngeal nerve. 
For the 8 RTCs we treated, both transisthmic approach and vertical method were 
used, by choosing as the case. We did not perform moving shot technique in the 
treatment of RTCs but the electrode was held fixed during the treatment. In this way 
we have exploited the heating effect due to the presence of perilesional fibrosis linked 
to previous surgery and radiation therapy in the neck.  
According to other investigators [17,42] we reported no recurrent disease at RF sites in 
our small group of patients with RTCs with a mean follow-up of 13 months. 
However, some authors [19] experienced tumoral regrowth in 2 of 15 treated cases, 
including one where complete ablation was initially obtained. The factors that cause 
tumor regrowth are unclear. Park at al. [19] demonstrated that there was no marked 
difference in techniques such as ablation time or RF power output between the 
masses that responded to therapy versus the ones that did not in their study.  
They hypothesized that is likely that regrowth is related to tumour biological 
behaviours. Thus, RFA is only recommended in the treatment of histologically well-
differentiated tumours, and there is no evidence of efficacy of RFA in the treatment 
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of poorly differentiated tumours or in medullary cancers. According to these findings, 
we included in our study only recurrences from well-differentiated thyroid cancers. 
A therapeutic success was obtained in 5 out of 6 patients (83%) because 1/6 RTC 
presented a VRR <50%; this is explained by the fact that the end point of our study, 
as previously suggested [17–20], was volume reduction and local control of cancer in 
patients with RTCs.  
One patient was lost from follow-up to the onset of severe lung infection and 
respiratory failure and another patient presented disease progression in other sites 
except the RF site and has been managed with systemic therapy in another Institution. 
Three of our patients had dysphonia after treatment of a recurrence in the surgical 
bed. Dupuy et al. [17] and Monchik et al. [18] also reported that one patient had 
dysphonia after treatment of a surgical bed tumor. These findings suggest that RFA is 
less safe in the surgical bed than in the lateral aspect of the neck. During RFA of the 
lateral aspect of the neck, the vagus nerve can be damaged, especially when the nerve 
is close to the tumor. At ultrasound examination, however, the vagus nerve is well 
visualized within the carotid sheath, usually posterolateral to the common carotid 
artery and posteromedial to the internal jugular vein. Careful attention to the vagus 
nerve during ablation can prevent vagus nerve injury [54,55]. In contrast, in the surgical 
bed, the recurrent laryngeal nerve is not visualized at ultrasound examination, and the 
nerve is more vulnerable to thermal injury. 
Our study had several limitations. The first limitation was a relatively short-term 
follow-up period. Nodule regrowth may be possible during longterm follow-up 
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periods, thus further results should be verified. Another limitation was that our 
sample size was small and might not be reflective of a larger population of 
symptomatic thyroid nodules and recurrent thyroid cancers. 
In addition, selection bias is inevitable. Regarding to RTCs, we treated small lesions 
likely providing more favourable results. Further works are needed to fully evaluate 
the RFA in inoperable RTCs because of the indolent nature of the disease and low 
mortality rate. 
 
CONCLUSION 
Although surgery is the standard treatment of symptomatic benign thyroid nodules 
and locally metastatic thyroid cancer, RFA is effective for symptoms relief and 
locoregional control of recurrences. RFA reduced the tumor volume significantly and 
demonstrated also to be a safe procedure. However, RFA is less safe for central than 
for lateral neck tumors, and we recommend that caution be exercised in the treatment 
of lesions that may be in close proximity to the recurrent laryngeal nerve. 
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